Full text is available at the source.
Trends in utilization patterns of newer glucose-lowering drugs in US adults with type 2 diabetes and a history of coronary heart disease or heart failure: 2005–2019
Use of newer blood sugar medicines over time in US adults with type 2 diabetes and heart disease or heart failure from 2005 to 2019
AI simplified
Abstract
In 2019, 60% of individuals with type 2 diabetes and a history of cardiovascular disease did not use newer glucose-lowering drugs.
- The use of GLP-1 receptor agonists increased from 3% in 2008 to 21% in 2019.
- The use of sodium-glucose cotransporter-2 inhibitors rose from 5% in 2014 to 12% in 2019.
- Dual use of both newer drug classes increased from 0.62% in 2015 to 6% in 2019.
- Despite the observed increases, the overall uptake of these newer drugs in 2019 was less than 40%.
- Variation in insurance type was associated with the low usage of these treatments among eligible individuals.
AI simplified